{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:08:09Z","timestamp":1792141689736,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.htct.2020.05.009","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T17:03:38Z","timestamp":1595437418000},"page":"185-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? \u2013 Literature review"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9951-587X","authenticated-orcid":false,"given":"Luana Mota","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaderson Lima","family":"Cerezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1747-4443","authenticated-orcid":false,"given":"Mailine","family":"Gehrcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.htct.2020.05.009_bib0185","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1590\/S1516-84842009005000013","article-title":"Mieloma m\u00faltiplo: caracter\u00edsticas cl\u00ednicas e laboratoriais ao diagn\u00f3stico e estudo progn\u00f3stico","volume":"31","author":"Silva","year":"2009","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"6","key":"10.1016\/j.htct.2020.05.009_bib0190","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.hoc.2014.08.010","article-title":"Multiple Myeloma","volume":"28","author":"Holstein","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.htct.2020.05.009_bib0195","first-page":"58","article-title":"Mieloma m\u00faltiplo: diagn\u00f3stico e tratamento","volume":"19","author":"Von Sucro","year":"2009","journal-title":"Rev Med Minas Gerais"},{"issue":"12","key":"10.1016\/j.htct.2020.05.009_bib0200","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.htct.2020.05.009_bib0205","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.htct.2020.05.009_bib0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.htct.2019.09.002","article-title":"Multiple myeloma and infection: this association is still close","volume":"41","author":"Garnica","year":"2019","journal-title":"Hematol Transf Cell Therap"},{"issue":"4","key":"10.1016\/j.htct.2020.05.009_bib0215","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.htct.2019.02.005","article-title":"Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan","volume":"41","author":"Zahid","year":"2019","journal-title":"Hematol Transf Cell Therap"},{"issue":"8","key":"10.1016\/j.htct.2020.05.009_bib0220","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections","volume":"47","author":"Sch\u00fctt","year":"2009","journal-title":"Leukem Lymphom"},{"issue":"21","key":"10.1016\/j.htct.2020.05.009_bib0225","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.htct.2020.05.009_bib0230","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.htct.2020.05.009_bib0235","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2020.05.009_bib0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.htct.2020.05.009_bib0245","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.htct.2020.05.009_bib0250","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.htct.2020.05.009_bib0255","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3109\/10428194.2011.555027","article-title":"Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide","volume":"52","author":"Offidani","year":"2011","journal-title":"Leukem Lymphom"},{"issue":"13","key":"10.1016\/j.htct.2020.05.009_bib0260","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2020.05.009_bib0265","series-title":"Dalinvi - Bula atualizada 09\/03\/2020","author":"Anvisa","year":"2020"},{"issue":"9","key":"10.1016\/j.htct.2020.05.009_bib0270","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.4049\/jimmunol.161.9.4702","article-title":"Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells","volume":"161","author":"Konopleva","year":"1998","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.htct.2020.05.009_bib0275","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.htct.2020.05.009_bib0280","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tracli.2017.12.001","article-title":"Daratumumab: therapeutic asset, biological trap!","volume":"25","author":"Deneys","year":"2018","journal-title":"Transfus Clin Biol"},{"issue":"2","key":"10.1016\/j.htct.2020.05.009_bib0285","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.advms.2019.05.001","article-title":"Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma","volume":"64","author":"Salomon-Perzy\u0144ski","year":"2019","journal-title":"Adv Med Sci"},{"issue":"2","key":"10.1016\/j.htct.2020.05.009_bib0290","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11899-018-0443-0","article-title":"Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies","volume":"13","author":"McCullough","year":"2018","journal-title":"Curr Hematol Malignan Rep"},{"issue":"1","key":"10.1016\/j.htct.2020.05.009_bib0295","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ejh.12551","article-title":"Cytomegalovirus reactivation in patients with multiple myeloma","volume":"96","author":"Hasegawa","year":"2016","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.htct.2020.05.009_bib0300","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1590\/S0104-07072008000400018","article-title":"Revis\u00e3o integrativa: m\u00e9todo de pesquisa para incorpora\u00e7\u00e3o de evid\u00eancias na sa\u00fade e na enfermagem","volume":"17","author":"Mendes","year":"2008","journal-title":"Text Cont Enferm"},{"issue":"3","key":"10.1016\/j.htct.2020.05.009_bib0305","first-page":"349","article-title":"Hipoglicemia Neonatal: Revis\u00e3o Integrativa","volume":"19","author":"Bordignon","year":"2018","journal-title":"Disciplinar Scient"},{"key":"10.1016\/j.htct.2020.05.009_bib0310","series-title":"Evidence-based practice in nursing & healthcare: a guide to best practice","first-page":"3","article-title":"Making the case for evidence-based practice","author":"Melnyk","year":"2005"},{"issue":"1","key":"10.1016\/j.htct.2020.05.009_bib0315","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.clml.2018.10.002","article-title":"Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment","volume":"19","author":"Frerichs","year":"2018","journal-title":"Clin Lymphom Myelom Leukem"},{"key":"10.1016\/j.htct.2020.05.009_bib0320","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/ejh.13164","article-title":"Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma","volume":"101","author":"Lavi","year":"2018","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.htct.2020.05.009_bib0325","doi-asserted-by":"crossref","first-page":"e0211927","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.htct.2020.05.009_bib0330","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00277-019-03645-7","article-title":"Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma","volume":"98","author":"Nakagawa","year":"2019","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.htct.2020.05.009_bib0335","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.htct.2020.05.009_bib0340","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.htct.2020.05.009_bib0345","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2020.05.009_bib0350","first-page":"31","article-title":"Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (RRMM; Pollux)","volume":"103","author":"Moreau","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.htct.2020.05.009_bib0355","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.htct.2020.05.009_bib0360","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/tid.12162","article-title":"High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network","volume":"16","author":"Marchesi","year":"2014","journal-title":"Transplant Infecti Dis"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137920300833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137920300833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:33:11Z","timestamp":1762867991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137920300833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2531137920300833"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2020.05.009","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? \u2013 Literature review","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2020.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}